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INTRODUCTION 
Transurethral Resection Of Prostate (TURP) is the surgical procedure 
done for benign prostatic hypertrophy. The standard anaesthetic technique 
for TURP is subarachnoid block
1
.  Lignocaine and Bupivacaine are the local 
anaesthetic drugs used to achieve the subarachnoid block. Adjuvants are a 
different pharmacological class of drugs, which are used to enhance and 
prolong analgesia, to lower the dose requirements and to reduce the dose 
dependent side effects. Many drugs have been tried as spinal adjuvants. They 
are Opioids, Sodium bicarbonate, Ketamine, Neostigmine, Midazolam, 
Clonidine and the latest inclusion is Dexmedetomidine. 
Initially opioids have been the standard choice as spinal adjuvant. But 
since there were many side effects and complications like early and late 
depression of ventilation, pruritus, nausea, vomiting, urinary retention,   
central nervous system excitation, delayed gastric emptying and ocular 
dysfunction, there is an active search for an alternative ideal adjuvant which 
is devoid of these side effects and complications. 
Preservative free Dexmedetomidine when administered into 
subarachnoid space produce analgesia.  Activation of post synaptic alpha 2 
receptors in the substantia gelatinosa of the spinal cord is the presumed 
mechanism by which it produces analgesia. 
Dexmedetomidine at appropriate doses when used as an adjuvant with 
Bupivacaine in subarachnoid block seems to prolong the duration of surgical 
anaesthesia and postoperative analgesia. The side effects like dry mouth, 
hypotension, bradycardia, are not usual in this dose.  The added advantages 
are sedation and prevent shivering. 
 Both Clonidine and Dexmedetomidine belong to the same group, α2 
agonists. They cause sedation and analgesia, in that Dexmedetomidine 
produces more analgesia and sedation because of its high selectivity to α2A 
receptor compared to Clonidine. 
           This study has been taken to compare Dexmedetomidine as well as 
Clonidine as spinal adjuvants with Bupivacaine.  
 
 
AIM OF THE STUDY 
 
    The aim of this study is to compare the onset and duration of 
sensory and motor block, hemodynamic changes and level of sedation 
following intrathecal Bupivacaine supplemented with either 
Dexmedetomidine or Clonidine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANATOMY OF SUBARACHNOID SPACE 
 Subarachnoid block
3
 is the regional anesthesia obtained by blocking 
the spinal nerves. In this block the anesthetic agents are deposited in the 
subarachnoid space and act on the spinal nerve roots. 
 Applied anatomy of vertebral canal: 
 Vertebral canal
2, 3
 extends from foramen magnum to the sacral hiatus 
and it protects the spinal cord. 
 The vertebral column comprises of 33 vertebrae (7-cervical, 12-
thoracic, 5-lumbar, 5-fused sacral and 4-coccygeal) and has four curves. In 
that, Cervical and lumbar curves are convex anteriorly and thoracic & sacral 
curves are convex posteriorly. The curves of the vertebral column influence 
the spread of the local anaesthetic in the subarachnoid space. 
 Each vertebra is composed of a body separated from the adjacent 
vertebra by intervertebral disc and formed by pedicles and lamina, which 
surround and protect the cord laterally and posteriorly. 
 The vertebral column is bound together by several ligaments. The 
ligaments 
5, 6
 are, 
1. Supraspinous ligament – passes longitudinally over the tips of the 
spinous processes from C7 to the sacrum. 
2. Interspinous ligament – connects the adjoining spinous processes 
together.  
 VERTEBRAL COLUMN 
 
 
 
 
 
 
 
 
  
3. Ligamentum Flavum – known as yellow ligament, connects the 
adjacent lamina composed of yellow elastic fibers. They become 
progressively thicker from above downwards. 
4. Posterior longitudinal ligament – It is on the posterior surface of 
bodies of vertebra. 
5. Anterior longitudinal ligament – It runs along the front of the vertebral 
bodies. 
There are seven projections from these vertebral (or) neural arches. 
They are, 
a) Three muscular processes – (2-Transverse processes, 1-spinous 
process for the attachment of muscle and ligaments). 
b) Four articular processes – Two upper & two lower which in the 
lumbar region prevent rotation but allow limited flexion and extension 
between contiguous vertebrae. 
Vertebral canal is formed by these structures has deficiencies 
posteriorly in the midline called inter laminar foramina which enlarge during 
flexion making it accessible for the passage of spinal needle. The direction 
of spinous process determines the direction of spinal needle. 
 
 
 
 
SPINAL CORD: 
 Spinal cord
 7, 8
 is the direct continuation of the medulla oblongata 
extending from the upper border of the atlas to the first lumber vertebra 
below where there is a bunch of nerve roots termed cauda equina. Spinal 
nerves are 31 pairs totally. 
 8  –  Cervical 
 12  –  Thoracic 
 5  –  Lumbar 
 5  –  Sacral 
 1  –  Coccygeal          
 Each of the spinal nerve is composed of anterior and posterior roots 
which unite at the intervertebral foramina and forming a nerve trunk. 
Membranes covering the spinal cord from without are duramater, 
arachnoidmater and piamater. Dura and arachnoidmater end at S2 level. 
Piamater is closely applied to the spinal cord. 
 An important factor that determines the spread of drug in 
cerebrospinal fluid is the baricity of the solution. Baricity is the density of 
the solution in relation to cerebrospinal fluid, the density of the solution is 
the mass of drug (gram) per ml of the solution. 
 
 
 
PHYSIOLOGY OF SUBARACHNOID BLOCK 
 Subarachnoid block
9-17
 implies the temporary interruption of nerve 
transmission within the subarachnoid space by injection of local 
anaesthetics.
9
 The blockade of nerve fibers occurs in the order of 
Temperature, Pain, proprioceptive and then motor fibers.   
 
FACTORS INFLUENCING BLOCK HEIGHT:  
11
 
 a - Site of injection  
 b - Angulations’ of needle  
 c - Characteristic of local anaesthetic- Baricity 
 d - Dose of local anaesthetic 
 e - Position of the patient during and after injection 
 f - Anatomic configuration of spinal column. 
 g - Patient height (at extremes) 
 h - Volume of cerebrospinal fluid 
 i - Reduced cerebrospinal fluid with increased intra abdominal  
    pressure (e.g. Pregnancy) 
 
  
SUBARACHNOID BLOCK 
 
 
 
 
 
 
 
 
  
  
a) Effects on Cardio Vascular System: 
 Most important physiological responses
9-13
 to subarachnoid block 
involve cardiovascular system due to combined effect of autonomic 
denervation, higher level of neural block, added effect of vagal innervation. 
 Local anaesthetics and vasoactive substances administered in small 
doses intrathercally leads to direct cardiovascular effect. 
 Level of sympathetic denervation determines the magnitude of 
cardiovascular system responses, but the relationship is neither predictable 
nor precise. 
 Sympathetic denervation produces venodilatation and arteriolar 
dilatation which produces fall in blood pressure. 
 Due to Bainbridge reflex, the fall in blood pressure is associated with 
bradycardia, blockade of cardiac sympathetic fibers from T1-T4 is an 
additional factor that causes bradycardia.  
b) Effects on Respiratory System:  
 Respiration is not depressed normally. High spinal
14, 15, 16
 can cause 
paralysis of intercostal muscles but the resting tidal volume, maximum 
inspiratory volume, respiratory rate, negative intrapleural pressure and also 
the phrenic nerve are unaffected. Hypoxia may accompany hypotension and 
is corrected by oxygen administration via face mask. 
 
c) Gastro Intestinal Effect:  
 Preganglionic fibers from T5-L1 are inhibitory to gut
16, 17
. So in 
sympathetic blockade the small intestine contracts with relaxed sphincters 
and peristalsis remains normal. Handling of viscera causes discomfort and 
bradycardia since vagus is not blocked. 
d) Hepatic and Renal Effects:  
 The hepatic blood flow
17
 decreases and is directly proportional to the 
decrease in blood pressure. Renal blood flow is maintained by auto 
regulation and does not decrease till mean arterial pressure falls below 
50mmHg. 
e) Genito Urinary System:           
 Sphincters of bladder are not relaxed, and the ureteric tone is not 
greatly altered. Urinary retention occurs, Penis is often engorged. Uterine 
tone is unchanged in pregnancy. In the absence of hypotension spinal 
anaesthesia has got no effect on the progress of labour and uterine blood 
flow.  
 
f) Metabolic and hormonal effect:  
 Spinal anaesthesia blocks the hormonal and metabolic responses
17
 to 
nociceptive stimuli arising from the operative site. It minimizes the rise in 
blood sugar, coritsol, catecholamine, and renin and aldosterone release 
which is associated with stress. Post operative negative nitrogen balance and 
secretion of antidiuretic hormone are inhibited.  
g) Thermo Regulation:  
 Hypothermia
17
 results from heat loss due to vasodilatation in the cold 
environment. 
 
 
 
 
 
 
 
  
TRANSURETHRAL RESECTION OF PROSTATE (TURP) 
SURGERIES: 
    Among the infraumbilical surgeries transurethral resection of prostate 
(TURP) surgeries one of the common sugeries in elderly. TURP surgical 
procedure is insertion of cystoscope and resection of enlarged prostate using 
electrical cautary through urethra.  
The usual of anaesthetic plan is subarachnoid block for TURP 
surgeries, because of its advantage over the general anaesthesia
18
. 
Advantages are following:  
1. Can look for the water overload or TURP Syndrome by assessing 
the higher function. 
2. Can assess the bladder perforation 
3. Reduce the blood loss  
4. Reduces the incidence of thrombosis. 
 
PHARMACOLOGY OF DRUGS 
BUPIVACAINE:
 
 
 Bupivacaine
19-28
 is an amide linked local anaesthetic. It is a 
hydrochloride salt of 1-butyl-N-(2, 6-dimethylphenyl) piperidine-2- 
carboxamide and is presented as a racemic mixture. 
 It was synthesized by Ekenstem in 1957. 
 A first report of its use was published in 1963 by Telivuo. 
 It is derived from Mepivacaine and is very stable compound and may 
be autoclaved repeatedly. 
Properties: 
Pka      - 8.1 
Molecular weight   -  288  
Protein binding    - 95% 
Lipid solubility   -  28 
Elimination half life  -  210mts 
Toxic plasma concentration -  >3µg/ml 
Approximate duration of action -  175mts 
  
 
 
 
Availability: 
 Ampoules - 0.5% Bupivacaine hydrochloride 4cc 
- 0.5% Bupivacaine hydrochloride with      
Dextrose (heavy) 4cc 
Vials  -   0.25% and 0.5% Bupivacaine hydrochloride  
    20cc 
 Dosage -   Maximum dosage 3mg/kg of body weight. 
Uses: 
20
 
 Spinal anaesthesia 
 Epidural anaesthesia 
 Caudal anaesthesia 
 Peripheral nerve block 
Onset time and duration of action:  
Site of action Onset (minutes)
 20
 Duration (minutes) 
Intrathecal 5 90 - 120 
Epidural 15 – 20 165 - 225 
Brachial plexus 10 – 20 600 
 
 
 
 
Pharmacokinetics:  
 Once injected intrathecally, it gets absorbed
21
 by the nerve rootlets and 
produces the desired effect. It is rapidly absorbed from the site of injection, 
but the rate of absorption depends on the vascularity at the site. 
 High lipid solubility of Bupivacaine makes it easy for nerve and 
vascular tissue penetration. 
 80-95% of the absorbed Bupivacaive binds to the plasma proteins. 
Biotransformation:  
 Metabolism
22
 of Bupivacaine include aromatic hydroxylation and 
conjugation. Only the N-dealkylated metabolite, N-desbutyl Bupivacaine has 
been measured in blood (or) urine after epidural (or) spinal anaesthesia. 
Alpha-1 acid glycoprotein is the most important plasma protein binding site 
of Bupivacaine and its concentration is increased by many clinical situations 
including post operative trauma. 
Excretion:  
 Bupivacaine is exceted
22
 through the kidney; 4-10% of the drug is 
excreted unchanged. 
 
 
 
 
 
Mode of Action:
 
 
a) Site of action: 
i) The spinal nerve rootlets 
23, 24
 have fine nerve filaments. And it has 
large surface area which are exposed to the local anaesthetics. 
ii) Posterior and lateral aspects of the spinal cord itself. 
b) Sodium Channel blockade: 
 They impede sodium ion access to the axon interior by occluding the 
transmembrane sodium channels thus delaying the process of depolarization 
and axon remains polarized. It is a non-depolarization blockade.     
Pharmacodynamics: 
 It has got a longer duration of action but a slower onset. 
Cardiovascular System:
 
 
 It reduces cardiac output
25
 by reducing the sympathetic tone, by 
slowing the heart rate and by reducing the venous return, it produces a fall in 
arterial blood pressure but it is relatively slow and is seldom very profound. 
It produces a fall in central venous pressure. It causes an increase in lower 
limb blood flow. It causes a reduction in incidence of deep vein thrombosis. 
 
 
 
 
 
  
Respiratory System: 
          It relaxes bronchial smooth muscle 
25
. Apnea can results from 
phrenic and intercostal nerve paralysis or depression of the medullary 
respiratory center following direct exposure to drug. 
Gastro intestinal tract:  
 There is an increase in gastro intestinal motility and the emptying of 
the gastric contents is better
25
.   
 Toxicity:  
 Toxicity
26 - 28
 is related to plasma level of unbound drug and more 
likely due to an inadvertent intravenous injection. Systemic toxicity reactions 
primarily involve central nervous system and cardio vascular system. The 
blood level required to produce central nervous system toxicity is less than 
that required to produce circulatory collapse. 
Central Nervous System Toxicity: 
        Early symptoms are circumoral numbness, tongue paresthesia, and 
dizziness. Sensory complaints include tinnitus and blurred vision. Excitatory 
signs (restlessness, agitation, nervousness, paranoia) often precede central 
nervous system depression (slurred speech, drowsiness, unconsciousness) 
28
. 
Muscle twitching heralds the onset of tonic clonic seizures. Respiratory 
arrest often follows. The excitatory reactions are the result of selective 
blockade of inhibitory pathways. 
Cardiovascular System Toxicity:  
 The rate of depolarization in fast conducting tissue of purkinje fibres 
and ventricular muscle is decreased. The rate of recovery of Bupivacaine 
induced block is slower than that of lignocaine. Extremely high 
concentration of the drug causes sinus bradycardia, hypotension, 
atrioventricular heart block, idioventricular rhythms, and life threatening 
arrhythmias such as ventricular tachycardia, ventricular fibrillation and 
cardiac arrest. 
 
  
  
CLONIDINE HYDROCHLORIDE
Introduction:  
             Clonidine hydrochloride
alpha -2 agonist introduced in early 1960s, it was during its use as a nasal 
decongestant that its anti
Subsequently more insights into the pharmacological properties have led t
its use in clinical anaesthesia practice as well. 
          
29
Clonidine hydrochloride
mesomeric compound. The chemical name is
-2- imidazoline hydrochloride. The structural formul
   The molecular weight is 266.56. 
white, crystalline substance, soluble in alcohol and water. 
improves the quality of anaesthesia, provides a more stable cardiovascular 
course during anaesthesia, presumably because of their sympatholytic effect 
reduces the dose requirement of the anaesthetic agent
  
29 - 34
 is a centrally acting selective partial 
- hypertensive property was found out. 
 
 is an imidazoline compound and exists as a 
 2- (2, 6- dichlorophenylamino) 
a is C9H9C12N3HCl.
 
Clonidine  Hydrochloride 
Clonidine is an odourless, bitter, 
31. 
Clonidine
o 
 
Clonidine 
 may 
reduce the halothane MAC by up to 50% in a dose dependent manner.  
Clonidine potentiates the anaesthetic action of the local anaesthetics with 
fewer side effects in peripheral nerve blocks and central neuraxial blockade. 
 
Availability: 
       Clonidine is available as one ml ampoule, containing 150 micrograms. It 
should be stored below 25
o
c.  
 
Mechanism of action:  
        Clonidine is a centrally acting selective partial α2 adrenergic agonist
30
 
with a selectivity ratio of 220: 1 in favour of α2 receptors.  The three 
subtypes of α2 receptors are α2a, α2b, α2c. α2a receptors mediate sedation, 
analgesia, and sympatholysis . α2b receptors mediate vasoconstriction and 
anti- shivering. The antinociception response may reflect the activation of 
α2c receptors.   The drug is lipid soluble, penetrates the blood brain barrier 
to reach the hypothalamus and medulla when injected epidurally
30
.  It 
stimulates the inhibitory α2 adrenoreceptors to reduce the central neural 
transmission in the spinal neurons.  Inhibition of substance- P release is 
believed to be involved in the analgesic effect.  
  The α2 adrenoreceptors are located on the afferent terminals of both 
peripheral and spinal neurons in the superficial laminae of the spinal cord 
and within several brain stem nuclei implicated in analgesia
30
.  The 
superficial laminae contain three groups of neurons: tonic, adapting, single- 
spike firing, all of which receive their primary sensory input from Aδ and C 
fibers. Clonidine inhibits voltage gated Na+ and K+ channels and suppresses 
the generation of action potentials in tonic- firing spinal dorsal horn neurons, 
contributing to the analgesic effect. The ability of Clonidine to modify the 
function of potassium channels in the CNS (cell membrane become 
hyperpolarized) may be mechanism for profound decrease in anaesthetic 
requirements.  
            Another contribution to analgesic effect may be through the release 
of acetylcholine in the neuraxial region. The α2 adrenergic agonists also 
enhance analgesia from intraspinal Opioids. Sedation is produced by its 
action on locus ceruleus.  
         Clonidine affects the blood pressure
30, 32
 in a complex fashion after 
neuraxial or systemic administration because of opposing action at multiple 
sites.  In the nucleus tractus solitarius and locus ceruleus of the brain stem, 
activation of post- synaptic α2 adrenoreceptors reduces sympathetic drive. It 
also activates nor-adrenergic imidazoline preferring binding sites in the 
lateral reticular nucleus producing hypotension and anti- arrythmogenic 
action. In the periphery it acts on pre-synaptic α2 adrenoreceptors at 
sympathetic terminals reduces the release of nor-epinephrine causing 
vasorelaxation and reduced chronotropic drive. The brainstem and the 
peripheral effects of α2 adrenoreceptor stimulation are counterbalanced by 
the direct peripheral vasoconstriction through its action on α2 
adrenoreceptors from the circulating concentrations of Clonidine. 
           Sedation
31
 is a desired property. Clonidine produces a dose dependent 
sedation at the dose of 50 µg or more dose acts in less than 20 minutes 
regardless of the route of administration. 
Clonidine doesn’t induce profound respiratory depression even after 
massive dose. It does not potentiate respiratory depression from Opioids. 
In peripheral nerves it produces a minor degree of blockade at high 
concentrations with some preference for C- fibers in the peripheral nerves 
and this effect in part enhance the peripheral nerve block when added to 
local anaesthetics, probably because the α2adrenoreceptors are lacking on 
the axons of peripheral nerves. 
 
Pharmacokinetics:  
           Clonidine is well absorbed orally and is nearly 100% bio available 
and reaches peak plasma concentration within 60 to 90 minutes. The mean 
half life of the drug in plasma is about 9 to 12 hours, with approximately 
50% metabolized
34
 in the liver whereas is it is excreted in an unchanged 
form by the kidney, and its half- life can dramatically increase in the 
presence of impaired renal function.  
A transdermal delivery system is available in which the drug will be released 
at constant rate for about a week. Three or four days are required to achieve 
steady state concentration. 
Clonidine is highly lipid soluble and readily distributes into extra- vascular 
sites including the central nervous system. 
 
 300 micrograms intravenously over 10 min produces: 
    Distribution t ½    :    11 ± 9 minutes. 
    Elimination t½   :   9 ± 2 hour, 41 hours in severe  
           Renal dysfunction. 
    Volume of distribution  :   2.1 ± 0.4 l/kg 
    Plasma protein binding  :   20-40 % in vitro. 
    Metabolism   :   minor pathways with the major  
          metabolite – p - hydroxyClonidine. 
  Excretion:  
70% of the dose is mainly excreted in the form of unchanged in urine. 
So, the elimination t1/2 of Clonidine varies as a function of Creatinine 
clearance.  In subjects undergoing hemodialysis only 5% of the body 
Clonidine store is removed. 
 
 
 
Dosage Regimen;  
        Oral        -  3-5 µg/kg 
        Intramuscular  -  2 µg/kg 
        Intravenous         -  1-3 µg/kg 
       Epidural                - 1-2 µg/kg 
      Transdermal           - 0.1- 0.3 mg released per day  
 
Precautions: 
1. In patients with renal insufficiency, lower dose is needed.  
2. Sudden withdrawal of prolonged continuous epidural infusion 
produces hypertensive crisis
31
. So it should be gradually discontinued 
over 2 to 4 days. 
3. Use with caution in patients with cerebrovascular or coronary 
insufficiency. 
4. If a patient with beta blocker is on continuous epidural therapy, beta 
blocker should be withdrawn several days before discontinuation of 
epidural Clonidine. 
5. Intrathecal / epidural Clonidine often causes bradycardia. If 
symptomatic, it can be treated with inj. Atropine. 
  
 
 
Contraindications: 
1. Known hypersensitivity
 33
 to Clonidine or components of the product. 
2. In patients with bradyarrhythmia or AV block. 
3. Patients with severe cardiovascular disease 
4. Patients with cardiovascular / hemodynamic instability. 
 
Interactions:    
1. Clonidine may potentiate the CNS- depressive effect of alcohol, 
barbiturates or other sedative drugs. 
2. The hypotensive effects are potentiated by narcotics. 
3. Tricyclic antidepressants antagonize the hypotensive effects of 
Clonidine. 
4. Concominttent administration of Beta Blocker, Digoxin, can cause 
bradyarrythmias. 
6. Epidural Clonidine may prolong the duration of pharmacologic effects 
of epidural local anaesthetics, Opioids, Neostigmine and other drugs.  
 
 
 
 
 
 
 USES:  
1.    Preanaesthetic Medication: 
In oral Clonidine  Preanaesthetic medication (5 µg/kg ), it  (a) blunts 
reflex tachycardia associated with direct laryngoscopy for intubation 
of trachea, (b) decrease plasma catecholamine level, and (c) 
dramatically decrease anaesthetic requirements for inhaled  and 
injected drugs.  Clonidine also attenuates the rise in intraocular 
pressure associates with laryngoscopy and intubation.  
2. Epidural block:  Clonidine as a sole agent or in combination with 
Opioids or local anaesthetics provides excellent analgesia in labour 
analgesia. Epidural Clonidine is also indicated for the treatment 
intractable pain, which is unresponsive to maximum dose of oral or 
epidural opioid, as in patients with reflex sympathetic dystrophy, 
neuropathic pain.  
3. Spinal Anaesthesia: Clonidine combined with local anaesthetics 
improves the quality and duration of the block, minimize the 
tourniquet pain during lower limb surgery, and prevents shivering. 
4. Caudal Anaesthesia: Clonidine combined with local anaesthetics 
increases the duration of anaesthesia and analgesia by 2 or 3 times 
without hemodynamic side effects. Dose 2-3 µg/kg 
5. Peripheral Nerve Blocks: Clonidine prolongs the duration of 
anaesthesia and analgesia with local anaesthetics by two times in a 
dose of 75 to150 micro grams. 
9. Clonidine is used in the treatment of hypertensive crises 
10.  Diagnosis of pheochromocytoma- Clonidine, 0.3 mg will decrease the 
plasma concentrations of catecholamine in normal patients but not in 
the presence of pheochromocytoma. 
11. Treatment of shivering- Administration of Clonidine, 75 µg I.V. stops   
shivering by inhibiting thermoregulatory control. 
12.  Treatment of opioid and alcohol withdrawal syndrome  
 
 
Side Effects: 
1. The most common side effects are sedation and xerostomia.  
2. Cardiovascular complaints are bradycardia, hypotension, and ECG 
abnormalities like sinus node arrest, junctional bradycardia, and high 
degree AV block and arrhythmia are reported rarely. Occasionally 
require treatment of bradycardia with I.V anticholinergics. Orthostatic 
hypotension occurs rarely. 
3. Rebound hypertension- in abrupt discontinuation of Clonidine can 
result in rebound hypertension as soon as 8 hours and as late as 36 
hours after the last dose. Symptoms of nervousness, diaphoresis, 
headache, abdominal pain, and tachycardia often precede the actual 
increase in systemic blood pressure. Labetalol is useful in treatment of 
rebound hypertension. 
4. Skin rashes are occurs frequently. 
Over dosage and treatment: 
        There is no specific antidote for Clonidine over dosage. Supportive 
measures like atropine, ephedrine, and I.V. fluids are enough.   
          Yohimbine partially reverses the analgesia and sedation. But it will not 
reverse the blood pressure and heart rate changes produced by the epidural 
Clonidine. 
 
 
 
 
 
 
 
 
 
 
 DEXMEDETOMIDINE HYDROCHLORIDE: 
Introduction: 
Clonidine was initially introduced as antihypertensive. That is the 
most commonly used alpha 2 agonist by anaesthesiologists. 
Dexmedetomidine
33-49
 is the most recent agent in this group approved by 
FDA in 1999 for use in humans for analgesia and sedation. 
 Dexmedetomidine hydrochloride
33
 injection is a sterile, nonpyrogenic 
solution suitable for intravenous infusion following dilution. 
Dexmedetomidine hydrochloride is the S-enantiomer of medetomidine and is 
chemically described as (+)-4-(S)-[1-(2, 3-dimethylphenyl) ethyl]-1H-
imidazole monohydrochloride. Dexmedetomidine hydrochloride has a 
molecular weight of 236.7 and the empirical formula is C13H16N2• HCl. 
  
Dexmedetomidine Hydrochloride 
Dexmedetomidine hydrochloride
34, 35
 is a white or almost white 
powder that is freely soluble in water and has a pKa of 7.1. Its partition 
coefficient in-octanol: water at pH 7.4 is 2.89. Dexmedetomidine 
hydrochloride is supplied as a clear, colorless, isotonic solution with a pH of 
4.5 to 7.0.  
 
Availability:  
Each milliliter contains 100 µg of Dexmedetomidine and 9 mg of 
sodium chloride in water. The solution is preservative-free and contains no 
additives or chemical stabilizers. 
 
Mechanism of action: 
 The mechanism of action
34
 of Dexmedetomidine differs from 
Clonidine as it posses selective alpha 2-adrenoceptor agonism especially for 
the 2A subtype of this receptor, which causes it to be a much more effective 
sedative and analgesic agent than Clonidine. It stimulates the inhibitory α2 
adrenoreceptors to reduce the central neural transmission in the spinal 
neurons.  Inhibition of substance- P release is believed to be involved in the 
analgesic effect.    
The majority of patients receiving Dexmedetomidine were effectively 
sedated yet were easily arousable, a unique feature not observed with other 
sedatives
34
.  
Dexmedetomidine
36, 37 
 does not appear to have any direct effects on 
the heart. A biphasic cardiovascular response has been described after the 
administration of Dexmedetomidine. The bolus of 1 mcg/kg 
Dexmedetomidine initially results in a transient increase of the blood 
pressure and a reflex fall in heart rate, especially in younger, healthy 
patients. Stimulation of alpha β-2-adrenoceptor in vascular smooth muscle 
seems to be responsible for the initial rise in the blood pressure, which can 
be attenuated by a slow infusion.  
The initial response lasts for 5 to 10 minutes and is followed by a 
slight decrease in blood pressure due to the inhibition of the central 
sympathetic outflow. The presynaptic
38,39
  alpha 2-adrenoceptors are also 
stimulated decreasing the nor epinephrine release resulting in fall in blood 
pressure & heart rate. These effects may also be observed in the 
postoperative period, and can be easily managed with atropine, ephedrine 
and volume infusion.  
Pharmacokinetics:  
Dexmedetomidine undergoes almost complete hydroxylation through 
direct glucuronidation and cytochrome P450 metabolism in liver
40, 41
. 
Metabolites are excreted in the urine (about 95%) and in the feces 
(4%). The elimination half-life is approximately 2 hours.  
It may be necessary to decrease the dose in patients with hepatic 
failure, since hepatic failure will lower rates of metabolism of the active 
drug. In cases of renal failure, the metabolites may accumulate, and the 
effects of metabolites have not yet been studied.  
The average protein binding of Dexmedetomidine is 94%, with 
negligible protein binding displacement by Fentanyl, Ketorolac, 
Theophylline, Digoxin, and Lidocaine, drugs commonly used during 
anesthesia and in the ICU. 
 
Dose: 
The doses should be titrated to the desired clinical effect. For adult 
patients, Dexmedetomidine is generally initiated with a loading infusion of 1 
mcg/kg over 10 minutes, followed by a maintenance infusion of between 0.4 
to 0.7 µg/ kg/hr. 
42
 
 
Side Effects:  
Dexmedetomidine crosses the placenta and its safety is not established 
in pregnancy and in children. The common adverse effects
43
 of 
Dexmedetomidine include hypotension, hypertension, nausea, bradycardia, 
atrial fibrillation, hypoxia and various atrioventricular blocks. Most of these 
adverse effects occur during or briefly after bolus dose of the drug. Omitting 
or reducing the loading dose can reduce adverse effects. 
 
 
 
 
Uses:  
1. Use during anaesthesia
43,45,46,47
 Dexmedetomidine possesses 
anxiolytic, sedative, analgesic, and sympatholytic properties, it 
might be a used for premedication, especially for patients in whom 
preoperative stress is undesirable.  
2. Dexmedetomidine has also been found to be an effective drug for 
premedication before i.v regional anesthesia as it reduces patient 
anxiety, sympathoadrenal responses, and opioid analgesic 
requirements.  
3. For the intraoperative period, it is used in the dose 0.4 to 0.7 
µg/kg/hr. Dexmedetomidine, like Clonidine attenuates the stress-
induced sympathoadrenal responses to laryngoscopy, intubation 
and surgery and provides good hemodynamic stability.  
4. It potentiates the anaesthetic effects of all intraoperative 
anesthetics, regardless of method of administration (intravenous, 
volatile, or even regional block).  
5. Dexmedetomidine administration during anaesthesia maintains 
hemodynamic stability, allows lower doses of anesthetics and 
opiates to be used, resulting in more rapid recovery from anesthesia 
and a reduced need for pain medication in the PACU, thereby 
reducing the length of stay.  
6. Dexmedetomidine also provides intense analgesia during the 
postoperative period. The postoperative analgesic requirements 
were reduced by 50% in cardiac patients and the need for rescue 
Midazolam for sedation was diminished by 80%.  
7. Dexmedetomidine seems to have few respiratory side effects and it 
can be continued safely during extubation, spontaneously breathing 
patient.  
8. Like Clonidine, Dexmedetomidine is associated with a lower rate 
of shivering. 
9. Dexmedetomidine produces a powerful antinociceptive
48
 effect, 
mediated at the spinal level, while systemic redistribution of the 
drug leads to a hypnotic state with significant cardiorespiratory 
effects. 
10. Patients who received Dexmedetomidine in the intensive care unit 
were observed to be arousable and alert when stimulated from 
sedation and quickly return to their sleep-like state. 
 
 
REVIEW OF LITERATURE 
1. Kanzai et al
49
 , they compared the onset and duration of sensory 
block, as well as the hemodyanamic changes and level of sedation 
following intrathecal Bupivacaine supplemented with either 
Dexmedetomidine or Clonidine in transurethral resection of porostate 
surgeries.  
They monitored the time to reach the peak sensory and motor 
levels, and sensory and motor regression times. They recorded 
hemodynamic changes and the level of sedation. In the group where 
they supplemented with 3 µg Dexmedetomidine (group D) or 30 µg 
Clonidine (group C) had significantly faster the onset of motor block 
and long duration of sensory and motor block. The mean time of 
sensory regression to S1 segment and regression of motor block to 
bromage   0 were more in group D then in group C and group B( 
Group B Vs Group B and D p<0.001). The onset and regression time 
were not significant in group C and D. The mean arterial pressure, 
heart rate and level of sedation were similar in the three groups intra 
operatively and postoperatively. They came to conclusion that 
Dexmedetomidine (3µg) or Clonidine (30µg) when added to 
intrathecal Bupivacaine produces a similar prolongation in the 
duration of the motor and sensory block with preserved hemodynamic 
stability and lack of sedation. Acta Anaesthesiology Scandinavia 
2006: 50: 222-227   
2. Subhi M. Al-Ghanem et al
50
 they were conducted this study in 60 
patients to evaluate the onset and duration of sensory and motor block 
as well as operative analgesia and adverse effects of 
Dexmedetomidine (DXM) or fentanyl given intrathecally with plain 
0.5% Bupivacaine for spinal anesthesia.  
They selected pateients who underwent vaginal hysterectomy, 
vaginal wall repair and tension free vaginal tape were prospectively 
studied. Patients were randomly allocated to receive intrathecally 
either 10 mg isobaric Bupivacaine plus 5 µg Dexmedetomidine (group 
D n = 38) or 10 mg isobaric Bupivacaine plus 25 mg Fentanyl (group 
F n = 38), the onset time to reach peak sensory and motor level, the 
regression time for sensory and motor block, hemodynamic changes, 
and side effects were recorded. In that study they got result as follow 
as, patients in group D had significant longer sensory and motor block 
times than patients in group F. They concluded that the women 
undergoing vaginal reconstructive surgery under spinal analgesia, 10 
mg plain Bupivacaine supplemented with 5 µg Dexmetedomidine 
produces prolonged motor and sensory block compared with 25 µg 
fentanyl.  American Journal of Applied Sciences 6 (5): 882-887, 2009 
3. Ibrahim F. A. Khalifa et al
51
 they compared the Dexmedetomidine 
(5µ) and sufentanil(5µ)  as additive with the Bupivacaine heavy  for 
postoperative analgesia in patients undergoing inguinal hernia repair. 
He took two groups with 25 patients in each group. He  observed the 
heamodyanamic changes and time to reach the peak sensory level, 
time to reach the peak motor level, regression time to S1 dermatome, 
time to regress to bromage 0 and duration of post operative pain 
relieve were studied. The difference in pulse rate, mean arterial 
pressure is insignificant between the groups intraoperatively and 
postoperatively. None of the patients was experienced repiratory 
depression, hypoxemia or sedation score >2.  But the time to 
regression modified bromadge, and time reach S1 segment were 
significantly increased in Dexmedetomidine group. Time to reach 
peak sensory, peak motor level and duration of pain relief is 
statistically insignificant between two groups. And they finally 
concluded that 5µg of Dexmedetomidine is an attractive adjuvant to 
spinal Bupivacaine in surgical procedures especially in those that need 
long time with minimal side effects. Benha Medical Journal 2009 
4. Mustafa et al
52
. in that study 60 patients were studied for the effect of 
Dexmedetomidine added to spinal Bupivacaine for urological 
procedures. They allocated patients randomly in 3 groups, each 
receiving spinal 12.5mg combined with normal saline, 
Dexmedetomidine 5µg or Dexmedetomidine 10µg. the onset times to 
reach T10, the onset time to reach bromage 3 motor block, regression 
time to reach sensory level S1 and regression time to reach bromage 0 
were recorded. The time of sensory block to reach the T10 dermatome 
and time to reach bromage 3 were faster in 10µ Dexmedetomidine 
group compare to 5µg Dexmedetomidine group. The regression time 
to reach S1 dermatome and the regression time to reach bromage 0 
was significantly increased. And there were no significant side effects. 
So they concluded that Dexmedetomidine has a dose dependent effect 
on the onset and regression of sensory and motor block when used as 
an adjuvant to Bupivacaine in spinal anaesthesia. Saudi medical 
Journal 2009: vol 30 (3): 365-370.   
5. Dilek Memis et al
53
 designed a study to evaluate the effect of 
Dexmedetomidine when added to Lidocaine in IV regional anesthesia 
(IVRA). They investigated in the onset and duration of sensory and 
motor blocks, intraoperative-postoperative hemodynamic variables, 
and intraoperative-postoperative pain and sedation. Sensory and motor 
block onset and recovery times and anesthesia quality were noted. 
Shortened sensory and motor block onset times, prolonged sensory 
and motor block recovery times, and prolonged tolerance for the 
tourniquet were found in Dexmedetomidine group. Intrapostoperative 
analgesic requirements were significantly less in Dexmedetomidine 
group. The time to first analgesic requirements was significantly 
longer in Dexmedetomidine  group in the postoperative period. So 
they conclude that the addition of 0.5 µg/kg of Dexmedetomidine to 
Lidocaine for IVRA improves perioperative analgesia without causing 
side effects. Anesthesia Analgesia 2004; 98:835–40 
6. Stephan Strebel et al
54
 they examined the dose-response relationship 
of intrathecal Clonidine at small doses (≤150µg) with respect to 
prolonging Bupivacaine spinal anesthesia. They studied to establish 
the doses of intrathecal Clonidine that would produce clinically 
relevant prolongation of spinal anesthesia and pain relief without 
significant side effects. They took eighty orthopedic patients in 
randomly assigned into intrathecally receive isobaric 0.5% 
Bupivacaine 18 mg, plus saline (Group 1), Clonidine 37.5µg (Group 
2), Clonidine 75µg (Group 3), and Clonidine 150µg (Group 4). They 
conclude that small doses of intrathecal Clonidine (≤150µg) 
significantly prolong the anesthetic and analgesic effects of 
Bupivacaine in a dose-dependent manner and that 150µg of Clonidine 
seems to be the preferred dose, in terms of effect versus unwarranted 
side effects, when prolongation of spinal anesthesia is desired. 
Anesthesia Analgesia 2004; 99:1231–8 
7. In Sethi et al
55
 study they used maximum dose of Clonidine 70 µg in 
spinal anaesthesia with 0.5% Bupivacaine. They concluded that 
addition of Clonidine to Bupivacaine in the dose of 1 µg.kg-1 
significantly increases the duration of spinal analgesia as compared to 
Bupivacaine alone with clinically insignificant influence on 
haemodynamic parameters and level of sedation. Indian Journal of 
Anaesthesia 2007; 51 (5): 415-419. 
8. D. J. In Fogarty et
56
 al they had studied the anaesthetic and analgesic 
properties of intrathecal Clonidine and intrathecal morphine in patients 
undergoing total hip replacement under spinal anaesthesia. Intrathecal 
Clonidine prolonged the duration of spinal analgesia, but was 
markedly inferior to the intrathecal morphine in providing subsequent 
postoperative analgesia. British Journal of Anaesthesia 1993; 71: 661–
664 
MATERIALS AND METHODS 
 After getting the ethical committee approval the study was conducted 
in 60 patients undergoing elective TURP surgeries. It was a double blinded 
study in which patients were randomly allocated into three groups A, B and 
C by using the computer based randomization. After getting informed 
consent and explaining the procedure details to the patients, the anaesthetic 
technique was performed. 
INCLUSION CRITERIA: 
 Grade I prostatic hypertrophy with  duration of surgery less than one 
hour 
 Age 50 – 70 years. 
 ASA I and II. 
 
EXCLUSION CRITERIA : 
 Patient refusal 
 ASA III & IV patients 
 Known case of diabetics mellitus and hypertension.  
 Spinal deformity 
 H/o drug allergy 
 
 
 PREOPERATIVE PREPARATION: 
Routine preoperative assessment was done to all the patients, as for all 
elective surgery patients. Investigations were done prior to surgery are Blood 
Haemoglobin, Total Count, Differential Count, Blood Sugar, Blood Urea, 
Serum Creatinine, Serum Electrolytes, Chest X-Ray, Electrocardiogram And 
ECHO Cardiogram. 
Group A  
     -  Received Inj. 0.5% Bupivacaine 2.0 cc+     
   Normal saline 0.5cc = 2.5 cc 
Group B  
      - Received Inj. 0.5% Bupivacaine 2.0 cc +    
   Inj.Clonidine (30µg) 0.5cc = 2.5 cc 
Group C  
      -  Received Inj. Bupivacaine 2.0 cc+     
  Inj. Dexmedetomidine (5µg) 0.5cc=2.5 cc   
 
PROCEDURE DETAILS: 
 On the day of surgery, preoperative baseline parameters like Pulse 
Rate, Blood Pressure, Respiratory Rate were recorded. Intravenous line 
started with 18 gauge intra venous cannula in right dorsum of hand. All the 
patients were preloaded with 500 ml of Lactated Ringer solution. 
Following emergency drugs and equipments were kept ready before 
anaesthesia intervention. 
 Boyles machine with oxygen cylinder 
 Oxygen source 
 Laryngoscope with various blades 
 Airway in all sizes 
 Suction apparatus  
 Emergency drugs like ephedrine, dopamine, atropine and adrenaline 
 Inj. Clonidine diluted  to 2.5cc with sterile normal saline and made 
into 60µ/ml 
 Inj. Dexmedetomidine diluted to 10cc with sterile normal saline and 
made into 10µ/ml 
 Drug was diluted and was loaded by another person as per 
randomization. And this diluted drug was given to the performer in 
1ml (40units) insulin syringe. 
Patients were positioned in the right lateral position.  With strict 
aseptic precautions, after infiltration of 2ml of 2% lignocaine, lumbar 
puncture was done with Quincke standard 25 guage spinal needle. In all 
patients, in L3-L4 interspinous space. 
After ensuring free flow of CSF, first 0.5 ml (20units) of testing drug 
was injected. Following the testing drug, 2ml of 0.5% hyperbaric 
Bupivacaine was injected. 
After the injection, patients were placed in supine position. Level of 
sensory and motor block was assessed. All the patients received oxygen 
through face mask with 5 liter per minute. After 5 minutes patients were 
positioned in lithotomy. Then the surgeon was asked to proceed. 
 The level of sensory block was assessed by pin prick sensation using 
25G needle along the mid clavicular line bilaterally. 
The onset and duration of motor blockade was assessed by using modified 
bromage scale
57
. The scale is:  
0 – patient able to move the hip, knee and ankle. 
1 - Patient unable to move the hip. But able to move knee  and ankle. 
2 - Patient unable to move the hip and knee. But able to  move ankle. 
3 - Patient unable to move the hip, knee and ankle 
Time to peak sensory level is defined as the time to reach T 10 
dermatome (the highest dermatome). 
Intra operative mean arterial blood pressure (MAP) was recorded by 
putting blood pressure cuff in the left arm. The pulse rate (PR) and the 
oxygen saturation were recorded using pulse oxymeter.  The parameters 
were recorded every 2 minutes for 10 minutes followed by every 5 minutes 
for first hour, then every 15 minutes for second hour and every hourly till the 
first rescue analgesia after spinal block post operative intensive care unit. 
Hypotension is defined as decrease in systolic blood pressure by 30% 
from baseline or systolic blood pressure lower than 90 mmHg. Hypotension 
is treated with 6mg of intravenous ephedrine  
Bradycardia is defined as pulse rate <50 beats/minute and it is treated 
with 0.3mg intravenous atropine in increments. 
Level of sedation was evaluated intraoperatively and post operatively 
every 15 minutes for first three hours then hourly for next 8 hours by using 
Ramsay sedation score :
58
 
1 – Anxious and agitated or restless or both 
2 – Co-operative, oriented and calm 
3 – Responsive to commands only 
4 – Exhibiting brisk response to light glabellar tap or loud 
 auditory stimulus 
5 – Exhibiting a sluggish response to light glabellar tap or loud  
  auditory stimulus 
6 – Unresponsive.  
Pain was assessed by the verbal rating score every 15 minutes for 3 
hours then every hourly for 8 hours.  
 
 
 
 
 
 
Verbal Rating Score :
59
 
 0 – No pain 
 1 – Mild pain 
 2 – Moderate pain 
 3 – Severe pain 
The rescue analgesia for pain was given with inj. Diclofenac sodium 
1mg/kg intramuscularly when the patient feels verbal rating score mild pain. 
If patients had intraoperaive and postoperaive nausea vomiting and 
shivering, they were recorded. 
OBSERVATION AND RESULTS 
 In this randomized double blinded study conducted in 60 patients, the 
subjects were allocated in to three groups. 
Group A (Bupi+Placebo) 
-  Inj. 0.5% Bupivacaine 2.0 cc +      
  0.5 cc normal saline 
Group B (Bupi+Clo)  
- Inj. 0.5% Bupivacaine 2.0 cc +      
  0.5 cc Clonidine (30 µg)                
Group C (Bupi+Dex) 
- Inj.0.5% Bupivacaine 2.0 cc+       
  0.5 cc Inj. Dexmedetomidine (5µg) 
Statistical Tools : 
The information collected from the study was documented in a Master 
Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2008).  
 Using this software range, frequencies, percentages, means, standard 
deviations and ‘p’ values were calculated. ANNOVA t test was used to test 
the significance of difference between quantitative variables.  A 'p' value of 
less than 0.05 is taken to denote significant relationship. 
  
 
  
PATIENTS DEMOGRAPHICS 
Table 1 : AGE DISTRIBUTION 
AGE GROUP 
CASES  
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 
NO. % NO. % NO. % 
50-60 years 8 40 7 35 8 40 
61-70 years 12 60 13 65 12 60 
Total 20 100 20 100 20 100 
Mean 
SD 
67.25 
9.6 
67.1 
9.1 
66.6 
6.8 
 
GROUP A & B & C 0.969 P > 0.05 not significant 
GROUP A & B 1.000 P > 0.05 not significant 
GROUP B & C 0.923 P > 0.05 not significant 
GROUP A & C 0.897 P > 0.05 not significant 
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Age distribution in the Group A (Bupi+Placebo) mean age is 67.27 
years and standard deviation with 9.6 years. In group B the mean age is 67.1 
years and standard deviation with 9.1 years. In group C the mean is 66.6 and 
standard deviation with 6.8 years. The p values for three groups are not 
significant, so age groups in three groups are identical. 
TABLE 2  
HEIGHT AND WEIGHT 
 
 
Variables 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 
‘p’ 
mean S.D Mean S.D mean S.D 
Height(cms) 157 7.5 161 7.8 161 8.4 
0.191 not 
significant 
Weight(kgs) 60 4.9 59 4 59 5 
0.736 not 
significant 
 
 
For Height :  
 
GROUP A & B & C 0.191 P > 0.05 not significant 
GROUP A & B 0.107 P > 0.05 not significant 
GROUP B & C 1.000 P > 0.05 not significant 
GROUP A & C 0.120 P > 0.05 not significant 
 
 
  
 
For weight: 
GROUP A & B & C 0.736 P > 0.05 not significant 
GROUP A & B 0.484 P > 0.05 not significant 
GROUP B & C 1.000 P > 0.05 not significant 
GROUP A & C 0.527 P > 0.05 not significant 
In group A the mean height is 157cm with standard deviation of 7.5. 
In group B the mean height is 161 cm with standard deviation of 7.8. In 
group C the mean height is 161 cm with standard deviation of 8.4 
In group A the mean weight is 60 kg with standard deviation of 4.9. In 
group B the mean weight is 59 kg with standard deviation of 4. In group C 
the mean weight is 59 kg with standard deviation of 5. 
The 'p' values for the height and weight of the three groups are 
not significant, so the three groups are identical. 
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TABLE 3 
ASA STATUS 
ASA 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 
No. % No. % No. % 
I 17 85% 16 80% 16 80% 
II 3 15% 4 20% 4 20% 
Total 20 100% 20 100% 20 100% 
 
In group A 85% belongs to ASA I and 15% ASA II 
In group B 80% belongs to ASA I and 20% ASA II 
In group C 80% belongs to ASAI and 20% ASA I 
clinically there is no significant difference in ASA distribution in all 
three groups. 
 
 
 
 
 
 
 
 
 
 
 
EFFICACY OF THE THREE GROUPS 
TABLE 4  
TIME TO PEAK SENSORY LEVEL IN MINUTES 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 
Mean S.D Mean S.D Mean S.D 
4.5 0.2 3.5 0.3 2.1 0.5 
 
GROUP A & B & C 0.001 P < 0.05  significant 
GROUP A & B 0.000 P < 0.05  significant 
GROUP B & C 0.000 P < 0.05  significant 
GROUP A & C 0.001 P < 0.05  significant 
(Time to teak sensory level is the time taken to reach the sensory level 
to T10 dermatome) 
In group A mean time to reach peak sensory level is 4.5 minutes with 
standard deviation of 0.2 minutes. In group B mean time to reach peak 
sensory level is 3.5 minutes with standard deviation of 0.3 minutes. In 
group C mean time to reach peak sensory level is 2.1 minutes with 
standard deviation of 0.5 minutes. P value shows there is significant 
change in the time for peak sensory level among the three groups. 
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TABLE 5 : TIME FOR MODIFIED BROMAGE 3 MOTOR BLOCK 
IN MINUTES 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 
Mean S.D Mean S.D Mean S.D 
5.3 0.3 4.4 0.3 2.9 0.4 
 
GROUP A & B & C 0.001 P < 0.05  significant 
GROUP A & B 0.000 P < 0.05  significant 
GROUP B & C 0.001 P < 0.05  significant 
GROUP A & C 0.001 P < 0.05  significant 
 (In modified Bromage 3 motor block, patients will be unable to move 
the hip, knee and ankle) 
 In group A mean time to reach for motor block to modified Bromage 3 
is 5.3 minutes with standard deviation of 0.3 minutes. In group B mean time 
to reach for motor block to modified Bromage 3 is 4.4 minutes with standard 
deviation of 0.3 minutes. In group C mean time to reach for motor block to 
modified Bromage 3 is 2.9 minutes with standard deviation of 0.4 minutes.  
 P value shows there is significant change in the time for motor 
block to modified bromage 3 among the three groups. 
 
  
0 1
Group A
Group B
Group C
g
ro
u
p
s
Time For Motor Block Bromage 3 
 
 
 
 
 
 
 
 
2 3 4 5 6
time in minutes
(modified)
 
Mean
TABLE 6  
TIME FOR TWO SEGMENT REGRESSION IN MINUTES 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 
Mean S.D Mean S.D Mean S.D 
59.3 10.3 91.5 9.6 105 9.7 
 
GROUP A & B & C 0.001 P < 0.05  significant 
GROUP A & B 0.001 P < 0.05  significant 
GROUP B & C 0.000 P < 0.05  significant 
GROUP A & C 0.001 P < 0.05  significant 
In group A mean time to sensory level to regress two dermatome level 
is 59.3 minutes with standard deviation of 10.3 minutes. In group B mean 
time to sensory level to regress two dermatome level is 91.5 minutes with 
standard deviation of 9.6 minutes. In group C mean time to sensory level 
to regress two dermatome level is 105 minutes with standard deviation of 
9.7 minutes.  
P value shows there is significant change in the time for peak 
sensory level among the three groups. 
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TABLE 7 
TIME TO REGRESS MODIFIED BROMAGE 0 MOTOR BLOCK  
IN MINUTES 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 
Mean S.D Mean S.D Mean S.D 
123 14.3 150.8 11.4 175.5 13.0 
 
GROUP A & B & C 0.001 P < 0.05  significant 
GROUP A & B 0.000 P < 0.05  significant 
GROUP B & C 0.001 P < 0.05  significant 
GROUP A & C 0.001 P < 0.05  significant 
(In modified Bromage 0 patient will be able to move the hip, knee and 
ankle) 
In group A mean time to regress motor block to modified bromage 0 
level is 123 minutes with standard deviation of 14.3 minutes. In group B 
mean time to regress motor block to modified bromage 0 level is 150.8 
minutes with standard deviation of 11.4 minutes. In group C mean time to 
regress motor block to modified bromage 0 level is 175.5 minutes with 
standard deviation of 13.0 minutes. P value shows there is significant 
change in the time to motor block to regress modified bromage 0 
level among the three groups. 
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 TABLE 8 
TIME TO REGRESS TO S1 LEVEL IN MINUTES 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 
Mean S.D Mean S.D Mean S.D 
119.3 11.4 147 13.4 169.5 8.6 
 
GROUP A & B & C 0.001 P < 0.05  significant 
GROUP A & B 0.001 P < 0.05  significant 
GROUP B & C 0.000 P < 0.05  significant 
GROUP A & C 0.001 P < 0.05  significant 
In group A mean time to regress sensory level to S1 is 119.3 minutes 
with standard deviation of 11.4 minutes. In group B mean time to regress 
sensory level to S1 is 147 minutes with standard deviation of 13.4 minutes. 
In group C mean time to regress sensory level to S1 is 169.5 minutes with 
standard deviation of 8.6 minutes. P value shows there is significant 
change in the time to motor block to regress bromage 0 level among the 
three groups. 
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 TABLE 9 
DURATION FOR REQUIREMENT OF RESCUE ANALGESIA  
IN MINUTES 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 
Mean S.D Mean S.D Mean S.D 
180.5 10.0 423 16.6 544.5 17.6 
 
 
GROUP A & B & C 0.001 P < 0.05  significant 
GROUP A & B 0.000 P < 0.05  significant 
GROUP B & C 0.001 P < 0.05  significant 
GROUP A & C 0.001 P < 0.05  significant 
In group A mean time for requirement of analgesia is 180.5 minutes 
with standard deviation of 10 minutes. In group B mean time for 
requirement of analgesia is 423 minutes with standard deviation of 16.6 
minutes. In group C mean time for requirement of analgesia is 544.5 
minutes with standard deviation of 17.6 minutes. P value shows there is 
significant change for time for requirement of analgesia among the 
three groups. 
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TABLE 10 
PULSE RATE PER MINUTE 
Time 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 'p' 
Value 
Mean S.D. Mean S.D. mean S.D. 
Pre 
operative 
79 19.1 80 5.1 88 4.7 0.036 
2min 80 19.3 81 5.4 85 4.2 0.374 
4 min 80 18.5 80 4.0 84 5.0 0.439 
6 min 79 17.8 81 6.4 84 5.2 0.379 
8 min 80 17.2 80 8.4 83 5.9 0.646 
10 min 80 17.0 81 5.9 84 4.8 0.477 
15 min 82 16.6 81 6.3 83 6.1 0.844 
30 min 80 13.5 83 5.1 83 7.6 0.512 
45 min 81 10.5 84 6.8 81 5.7 0.392 
60 min 85 8.5 84 7.4 82 8.3 0.494 
90 min 86 7.4 85 5.5 86 4.8 0.832 
120 min 89 9.3 86 7.2 85 4.1 0.197 
150 min 87 16.5 90 5.7 86 4.6 0.457 
180 min 89 22.1 91 5.1 86 4.8 0.030 
4 hours 86 7.5 85 7.1 84 4.4 0.600 
5 hours 84 5.9 84 4.8 84 3.1 1.000 
6 hours 85 4.9 85 7.6 85 3.7 1.000 
7 hours 83 5.4 88 5.1 85 3.3 0.006 
8 hours 85 4.4 84 5.8 85 3.7 0.742 
 
In the Group A initial pulse rate was 79 beats/ minute. In the Group B 
initial pulse rate was 80 beats/ minute. In the Group C initial pulse rate was 
88 beats/ minute.  
Clinically and statistically there is no decrease in Pulse Rate in all 
three groups. 
 
TABLE 11 
MEAN ARTERIAL PRESSURE IN mmHg 
Time 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 'p' 
value 
Mean S.D. Mean S.D. mean S.D. 
Pre 
operative 
122 27.7 115 7.1 123 7.1 0.277 
2min 116 26.1 108 8 116 7.6 0.212 
4 min 106 25.3 107 9.8 114 8.4 0.252 
6 min 108 26.4 104 11.4 113 12.0 0.292 
8 min 109 25.8 109 13.2 118 7.2 0.165 
10 min 111 24.5 111 9.9 118 5.3 0.301 
15 min 113 24 110 8.3 117 6.9 0.231 
30 min 113 19.8 112 6.8 118 7.8 0.486 
45 min 114 16.3 114 6.1 120 5.6 0.032 
60 min 118 14.2 113 7.5 119 7.6 0.392 
90 min 116 7.9 115 4.7 118 5.0 0.436 
120 min 115 5.2 118 8.8 118 4.0 0.612 
150 min 122 8.9 123 7.3 118 4.3 0.348 
180 min 126 15.9 121 4.2 116 4.8 0.321 
4 hours 122 10.6 119 4.7 117 4.6 0.686 
5 hours 121 6.6 119 4.7 117 5.3 0.834 
6 hours 122 7.9 116 3.6 117 4.6 0.808 
7 hours 125 8.5 118 5.5 118 4.7 0.325 
8 hours 125 8.3 122 5.5 118 4.1 0.841 
 
In the Group A initial mean systolic blood pressure was 122mmHg. 
And it is reached minimum of 108mmHg at 6
th
 minute. 
In the Group B initial mean systolic blood pressure was 115mmHg. 
And it is reached minimum of 104mmHg at 6
th
 minute. 
In the Group C initial mean systolic blood pressure was 123mmHg. 
And it is reached minimum of 113mmHg at 6
th
 minute. 
In Mean Systolic Blood Pressure, there is fall in group B in 2  to 8 th 
minute. But that was statistically and clinically not significant fall.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 12 
RESPIRATORY RATE 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 
Mean S.D Mean S.D Mean S.D 
14.8 1.3 14.8 1.2 15 0.9 
 
GROUP A & B & C 0.817 P > 0.05  not significant 
GROUP A & B 1.000 P > 0.05  not significant 
GROUP B & C 0.627 P > 0.05  not significant 
GROUP A & C 0.587 P > 0.05  not significant 
 
P values of three groups are not significant so changes in respiratory 
rate in the three groups are statistically insignificant. 
TABLE 13 
SPO2 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 
Mean S.D Mean S.D Mean S.D 
100 0.5 99 0.7 100 0.7 
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GROUP A & B & C 0.625 P > 0.05  not significant 
GROUP A & B 0.305 P > 0.05  not significant 
GROUP B & C 0.829 P > 0.05  not significant 
GROUP A & C 0.934 P > 0.05  not significant 
P values of three groups are not significant so changes in SPO2 in 
the three groups are statistically insignificant. 
TABLE 14 
RAMSAY SEDATION SCORE 
 
Ramsay 
Sedation Score 
Group-A 
(Bupi+Placebo) 
Group-B 
(Bupi+Clo) 
Group-C 
(Bupi+Dex) 
No. % No. % No. % 
1 
2 
3 
4 
5 
- 
20 
- 
- 
- 
- 
100 
- 
- 
- 
- 
20 
- 
- 
- 
- 
100 
- 
- 
- 
- 
20 
- 
- 
- 
- 
100 
- 
- 
- 
In all the three groups all the patients had Ramsay sedation score of 
2(Co-operative, oriented and calm). So there is no clinically difference 
in all three groups. 
 
 
 
DISCUSSION 
The newer Dexmedetomidine and Clonidine belong to the same 
family of α2 adrenoceptor agonists, but Dexmedetomidine has more α2A 
selective agonist property when compared to Clonidine.
60
 So the study was 
performed to compare the effects of Dexmedetomidine and Clonidine with 
spinal Bupivacaine. 
In our study, dose of Dexmedetomidine chosen was 5µg and dose of 
Clonidine was 30µg as additive to spinal Bupivacaine. There were very few 
studies done using Dexmedetomidine as an additive in spinal anaesthesia. 
61-
Eisenach et al
68
 had done animal studies with spinal Dexmedetomidine in the 
dose of 100µg. Kanzai et al
49
 did an early human study with 3 µg of 
Dexmedetomidine and he found it is equipotent to 30µg of Clonidine (1:10 
ratio)
 68,69
. Subhi et al
50
 chose 5µg of Dexmedetomidine as spinal additive in 
his studies. In both the above studies low dose of 3µg and 5µg of 
Dexmedetomidine were effective as an additive to spinal anaesthesia with 
least complication. This is the reason why we chose 5µg (low dose) 
Dexmedetomidine as a spinal additive. 
Subhi et al
50
 they had sample size of 38 people and they derived 
significant statistical results. Khalifa et al
51
 had sample size of 25 in each 
group and in Mustafa et al
52 
each group was allocated with 22, 21, 21 
persons. They also derived significant statistic results. Kanzai et al
49
 they 
studied 60 subjects in three groups (n=20) and they arrived reliable statistics 
with that n value. So we also decided to conduct the study with sample size 
of 20 subjects in each group. 
The results in our study showed that the supplementation of spinal 
Bupivacaine with either 5µg of Dexmedetomidine or 30µg of Clonidine 
significantly hastens the onset of sensory and motor block and also prolongs 
the both sensory and motor blockade when compared with spinal 
Bupivacaine alone in TURP surgeries. But the time to reach peak sensory 
and peak motor level is much shorter in Dexmedetomidine (5µg) group 
when compare to Clonidine (30µg) group. Kanzai et al
49
 used equipotent 
dose of Dexmedetomidine (3 µg) and Clonidine (30 µg)  as an additive to 
spinal Bupivacaine and he found the onset of sensory and motor blockade is 
faster  with Clonidine when compared to Dexmedetomidine group.  
Subhi et al
50
 they used Dexmedetomidine and Fentanyl as an additive 
to spinal anaesthesia in different groups and found Fentanyl group to have 
more faster  onset of peak sensory and motor level.  
In Mustafa et al
52
 they had three groups, Bupivacaine + placebo, 
Bupivacaine +5µg Dexmedetomidine and Bupivacaine + 10 µg 
Dexmedetomidine. In this study they found that 10 µg Dexmedetomidine 
group had the fastest onset of peak sensory and peak motor block compare 
with lower dose of Dexmedetomidine.  
We infer from the above studies that higher the dose of 
Dexmedetomidine as spinal, faster the onset of peak sensory and motor 
blockade. 
In our study when 10 mg of 0.5% Bupivacaine is added with 5µg of 
Dexmedetomidine it significantly prolongs the duration of sensory blockade, 
motor blockade and duration of post operative analgesia when compared to 
30µg of Clonidine when added with 10mg of 0.5% Bupivacaine. 
Similarly when 10 mg of 0.5% Bupivacaine added with 30µg of 
Clonidine, significantly prolongs the duration of sensory blockade, motor 
blockade and duration of post operative analgesia when compared to 10 mg 
0.5% of Bupivacaine with placebo group. 
In Kanzai et al
49
, Khalifa et al
51
 and Subhi et al
50s
 studies, they all have 
used Dexmedetomidine as spinal additive. The above three studies have 
compared Dexmedetomidine as spinal additive to Clonidine 30µg or 
sufentanil 5µg or Fentanyl 25µg, and they found in common, that 
Dexmedetomidine prolongs the spinal anaesthesia more when compared to 
all other three additives mentioned above.  
 In Mustafa et al
52
 they compared two doses of spinal 
Dexmedetomidine as spinal additive (5µg and 10µg). In that 10µg 
Dexmedetomidine group had prolonged sensory blockade, motor blockade 
and post operative analgesia compared to 5 µg Dexmedetomidine group. 
The mechanism by which intrathecal α2 adrenoceptor agonists 
prolong the motor sensory block of local anaesthetics is not well understood. 
It may be an additive or synergistic effect secondary to a different 
mechanism of action of the local anaesthetic. The local anaesthetic acts by 
blocking the sodium channels, whereas the 2adrenoceptor agonist acts by 
binding to pre-synaptic C- fibers and post-synaptic dorsal horn neurons
70-74
. 
These antinocieptive effects explain the prolongation of the sensory block 
when added to spinal anaesthsia. The prolongation of the motor block of 
spinal anaesthetics may result from the binding of α2 adrenoceptor agonists 
to motor neuron in the dorsal horn
75
 in the spinal cord. 
Most of the clinical experience in the use of intrathecal α2 
adrenoceptor agonists has been described with Clonidine
76-78
. Intrathecal 
Clonidine has a well established synergestic effect with local anesthectics. 
Studies using a combination of intrathecal Dexmedetomidine and local 
anaesthetics are few. In our study intrathecal Dexmedetomidine was selected 
based on Kanzai et al where he used 30µg and 3µg of Dexmedetomidine in 
intrathecal space. In Subhi et al, they used 5µg of Dexmedetomidine and 
25µg of Fentanyl as spinal additive with spinal Bupivacaine. Our results 
showed that the sensory and motor were blocks prolonged significantly 
Dexmedetomidine group when compared to Clonidine group. This result is 
against Kanzai et al because they used 3µg of Dexmedetomidine and 30µg 
of Clonidine. They hypothesized that 3µg of intrathecal Dexmedetomidine 
might be equipotent to 30µg of intrathecal Clonidine. Our study further 
supported by Subhi et al, where they had 10 mg plain Bupivacaine 
supplemented with 5 µg dexmetedomidine produces prolonged motor and 
sensory block compared with 25 µg Fentanyl. In al- Mustafa et al they had 
similar results in their study. In Khalifa et al they had similar results when 
they compared 5 µg of Dexmedetomidine and 5 µg of sufentanyl with spinal 
Bupivacaine. 
In our patients the addition of Dexmedetomidine or Clonidine to 
Bupivacaine causes initial fall in the blood pressure especially in Clonidine 
group. But fall is not clinically significant and they did not require 
vasopressor intra operatively or post operatively. An Intrathecal local 
anaesthetic blocks the sympathetic outflow and reduces the blood pressure. 
The sympathetic block is usually near maximal with the doses used for 
spinal anaesthesia. The addition of low dose of α2 agonist to a high dose of 
local anaesthetics does not further affect the near maximal sympatholysis
70
. 
Clonidine in the dose range 37.5 to 150 µg did not cause significant decrease 
in blood pressure when added to 18 mg of Bupivacaine compared with 
Bupivacaine alone
73
. In contrast more than 150 µg of Clonidine added to a 
low dose of Bupivacaine (5mg) yielded a greater decrease in blood pressure 
than Bupivacaine alone
78-80
. 
In our study we did not encounter bradycardia in any of the group. But 
in Kanzai et al one patient in Clonidine group and three patients in 
Dexmedetomidine group had bradycardia. Subhi et al encountered 
bradycardia in two patients in Dexmedetomidine group and 3 patients in 
Fentanyl group. Similarly in Khalifa et al two patients in each group (in 
Dexmedetomidine group and in Sufentanil group) had bradycardia. 
In Mustafa et al two patients in Bupivacaine alone group had 
bradycardia, one patient group added 5µg as spinal additive had bradycardia. 
But no one had bradycardia in the third group where 10µg Dexmedetomidine 
added as a spinal additive. In all the above studies what we have commonly 
seen is the clinically insignificant incidence of bradycardia of  lower doses of 
Dexmedetomidine.  
In our study none of our patients were drowsy. All the patients were 
co-operative, oriented and calm. This is supported by Kanzai et al, Subhi et 
al, Khalifa et al and Mustafa et al. In Mustafa et al even with 10µg of 
Dexmedetomidine as spinal additive did not produce any sedation in 
patients.  Intrathecally administered α2 agonists have a dose dependent 
sedative effect
81
. The doses of Clonidine and Dexmedetomidine selected in 
our study were at the lower end of dosing spectrum. This explains the lack of 
sedative effect in the study groups. 
 
 
 
 
 SUMMARY 
 
     This is a randomized double blinded study conducted in 60 patients of 
ASA I and II undergoing elective transurethral resection of prostate (TURP) 
surgeries. Patients were allocated in three groups. 
 Group A (Bupivacaine + sterile normal saline as placibo) 
Group B (Bupivacaine + Clonindine 30µg) 
Group C (Bupivacaine + Dexmedetomidine 5µg) 
    Parameters observed were time of onset of sensory block, time of onset of  
motor block, two segment regression time, duration of motor blockade, 
duration of sensory blockade, sedation score, duration of post operative 
analgesia, haemodynamic changes and side effects. 
1. The post operative analgesia was significantly prolonged in group C 
and was 364 minutes more than the group A and 121.5 minutes more 
than group B. 
2. The systolic blood pressure dropped during the early anaesthetic 
period but the fall was within the 30 percentage of basal systolic blood 
pressure. 
3. There was no significant fall in pulse rate in all group A, group B, 
and group c. 
4. No Sedation were observed in all three groups, but patient was 
comfortable, co-operative, oriented and calm.  
5. Neither respiratory depression nor decrease in saturation was 
observed in any of the group. 
 
 
  
CONCLUSION 
(i) Adding 30µg Clonidine or 5µg Dexmedetomidine to 10mg of 
Bupivacaine significantly prolongs the duration of post 
operative analgesia when compare to Bupivacaine alone in 
elective transurethral resection of prostate (TURP) surgeries. 
(ii) Bupivacaine with Dexmedetomidine prolongs significantly the 
duration of post operative analgesia when compared to 
Bupivacaine with Clonidine in spinal anaesthesia.  
(iii) Bupivacaine when used alone or with adjuants like Clonidine 
(30µg) or Dexmedetomidine (5µg) does not produce any 
appreciable side effects. 
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PROFORMA 
 
Name :       Height :  Date : 
Age :         Sex  :                Weight : 
I.P.No :   Diagnosis : 
ASA Status :                              Time of injection of drugs : 
Group :                              Duration of surgery : 
Time of incision:     Time of finishing  : 
 
 
Time of peak sensory block :         Time to regression two dermatome :      Time 
to regress S1 :   
 
Time of peak motor block(bromage3) :  Time to regress bromage 0 : 
                     
Intra–operative events : 
 
IV fluids : 
 
Ing. Ephedrine(6mg iv bolus) : 
 
Ing. Atrpin(0.6mg iv bolus) : 
 
 
 
 INTRA– OPERATIVE VITALS MONITORING 
 
Time interval (minutes) 
Sl. 
No 
Parameter 
Pre-
op 
2 4 6 8 10 15 20 25 30 35 40 45 50 55 60 
1. HR             
   
 
2. SBP                 
3. DBP                 
4. MAP                 
5. RR                 
6. Shivering                 
7. 
Ramsay 
sedation 
socring 
 
            
   
 
POST–OPERATIVE   MONINTORING 
Parameter Time interval (every  15 minutes for next hour,  
every hour till rescue analgesia) 
      
1. HR 
2. SBP 
3. DBP 
4. Pain Score : 
(Verbal Rating Scale) 
 0 – No Pain 
 1 – Mild Pain 
 3 – Severe Pain 
5.Ramsay sedation 
scoring 
1 - anxious and 
agitated or restless, or 
both 
2 - co-operative, 
oriented, and calm 
3 - responsive to 
commands only 
4 - exhibiting brisk 
response to light 
glabellar tap or loud 
auditory stimulus 
5 - exhibiting a 
sluggish response to 
light glabellar tap or 
loud auditory stimulus 
6 – unresponsive 
6. Nausea/Vomiting 
8. Adverse Effects:  
     
 
POST–OPERATIVE ANALGESICS CONSUMPTION 
Time of first rescue analgesic 
Inj. Diclofenac Sodium 1mg/kg I.M. 
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1 14821 A 69 M 148 69 I 16 99 2 4.5 5 135 60 135 180 
2 14949 A 62 M 156 53 I 14 100 2 4.75 5.25 120 45 105 195 
3 15397 A 62 M 163 59 I 16 99 2 4.25 5 120 60 120 195 
4 17762 A 68 M 148 59 I 15 100 2 4.25 5.75 135 75 120 180 
5 18402 A 56 M 162 68 I 15 100 2 4.5 5 120 75 105 180 
6 21057 A 62 M 168 58 II 16 100 2 4.75 5.25 120 60 105 195 
7 19001 A 55 M 162 62 I 13 100 2 4.5 5 135 45 105 180 
8 20521 A 58 M 158 68 I 12 99 2 4.25 5.25 105 60 120 165 
9 21061 A 68 M 155 56 I 14 100 2 4.5 5.75 135 45 120 180 
10 23520 A 65 M 164 58 I 15 99 2 4.75 5 120 60 135 180 
11 24986 A 63 M 162 64 II 16 99 2 4.75 5 120 75 120 165 
12 25593 A 58 M 168 63 I 13 100 2 4.5 5 105 60 120 180 
13 26736 A 55 M 156 58 I 14 100 2 4.25 5.25 90 45 105 180 
14 26566 A 69 M 149 53 II 14 100 2 4.5 5.25 135 60 120 165 
15 30441 A 61 M 145 55 I 15 100 2 4.5 5.75 150 60 135 195 
16 29510 A 67 M 166 61 I 15 100 2 4.5 5.75 135 60 120 180 
17 32542 A 60 M 150 66 I 14 100 2 4.25 5.75 135 75 135 180 
18 33885 A 65 M 148 63 I 15 99 2 4.25 5.25 120 60 135 165 
19 36226 A 60 M 159 59 I 16 100 2 4.75 5.5 120 45 105 190 
20 39734 A 50 M 149 56 I 17 100 2 4.5 5.25 105 60 120 180 
21 15406 B 66 M 167 64 I 15 100 2 3.5 4.25 135 90 150 420 
22 17773 B 70 M 148 60 II 16 100 2 3.25 4 150 75 135 420 
23 18993 B 55 M 156 58 I 15 100 2 3.5 4.5 135 90 150 390 
24 19879 B 61 M 167 57 I 14 98 2 3.25 4.5 150 90 150 420 
25 18659 B 67 M 168 55 II 15 100 2 4 5 150 90 165 420 
26 20442 B 54 M 166 54 I 16 100 2 3.75 4 150 105 165 420 
27 21226 B 63 M 163 57 I 13 100 2 3.75 4.5 165 105 150 390 
28 22150 B 66 M 169 52 I 15 100 2 2.5 3.5 165 75 135 420 
29 23040 B 60 M 158 66 II 16 100 2 3.75 4.5 135 90 150 420 
30 26234 B 55 M 166 57 I 16 100 2 3.25 4.25 150 90 135 450 
31 26202 B 70 M 168 64 I 14 100 2 3.25 4 165 90 150 420 
32 26556 B 68 M 146 63 II 15 99 2 3.5 4.75 150 105 150 420 
33 28140 B 54 M 154 55 I 16 100 2 3.5 4.25 150 90 135 420 
34 31504 B 57 M 156 61 I 14 100 2 3.75 4.5 135 90 150 450 
35 32184 B 62 M 152 64 I 15 100 2 3.75 4.25 165 105 165 420 
36 33558 B 65 M 163 59 I 16 100 2 3.25 4.5 165 90 150 450 
37 33553 B 59 M 166 62 I 14 99 2 3.5 4.75 135 90 150 420 
38 35102 B 69 M 163 54 I 15 100 2 4 4.75 165 75 105 420 
39 35201 B 60 M 169 59 I 13 100 2 3.5 4.5 150 105 150 420 
40 40019 B 65 M 147 56 I 12 100 2 3.25 4.25 150 90 150 450 
41 15403 C 60 M 142 63 I 15 100 2 2.5 3.5 165 90 165 540 
42 17521 C 61 M 147 60 I 16 100 2 1.5 2.5 180 105 165 540 
43 19643 C 57 M 155 58 I 17 100 2 2.25 3 180 105 165 510 
44 18968 C 65 M 166 50 I 15 100 2 2.75 3.5 165 105 165 510 
45 20194 C 65 M 168 55 I 16 100 2 2.5 3.5 195 120 180 540 
46 21044 C 59 M 159 56 I 14 99 2 2.75 3 180 105 180 540 
47 21365 C 60 M 148 58 I 14 99 2 1.5 2.5 165 90 165 570 
48 22184 C 58 M 155 52 I 15 99 2 1.75 2.75 195 90 165 540 
49 23172 C 61 M 167 59 I 14 100 2 3 3.5 195 105 180 540 
50 25729 C 62 M 163 54 I 14 100 2 1.5 2 165 120 165 570 
51 26727 C 58 M 168 60 I 14 100 2 2 3 180 120 165 540 
52 27790 C 68 M 169 56 I 15 100 2 2.5 3 180 105 180 540 
53 32533 C 65 M 168 57 II 15 100 2 1.25 2.5 165 105 165 570 
54 34621 C 63 M 157 53 I 16 100 2 2.5 3 195 105 165 540 
55 33552 C 58 M 168 66 I 14 100 2 2 2.5 165 105 180 540 
56 33534 C 65 M 164 69 II 15 100 2 2.5 3 180 120 165 540 
57 35084 C 59 M 169 62 I 16 99 2 2.25 3 165 90 150 570 
58 36849 C 55 M 166 64 II 14 100 2 2 3.25 150 105 165 570 
59 41241 C 65 M 156 65 I 15 100 2 1.75 2.5 165 105 180 540 
60 39672 C 64 M 169 55 II 16 100 2 2 2.75 180 105 180 540 
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148
21 A 69 M 148 69 I 134 125 126 120 126 128 122 120 124 128 115 122 114 120 127 125 130 136 120 
2 
149
49 A 62 M 156 53 I 125 125 114 116 114 118 120 124 116 118 114 123 118 124 125 111 123 119 122 
3 
153
97 A 62 M 163 59 I 130 125 128 130 122 126 124 120 118 126 123 112 110 111 124 121 125 121 110 
4 
177
62 A 68 M 148 59 I 125 125 118 114 116 120 114 118 120 126 111 105 122 119 111 127 111 115 122 
5 
184
02 A 56 M 162 68 I 112 110 104 96 92 114 120 112 114 122 126 111 115 122 109 119 116 126 120 
6 
210
57 A 62 M 168 58 II 107 100 96 92 94 94 96 105 110 116 114 119 117 121 130 119 113 123 115 
7 
190
01 A 55 M 162 62 I 120 118 110 122 124 118 112 116 118 112 114 115 115 121 119 113 109 124 118 
8 
205
21 A 58 M 158 68 I 123 117 110 118 116 119 123 120 119 122 120 112 122 110 106 124 118 120 126 
9 
210
61 A 68 M 155 56 I 129 124 122 120 123 120 126 116 118 120 114 113 124 119 116 109 117 125 123 
10 
235
20 A 65 M 164 58 I 110 100 96 92 94 98 110 118 119 116 124 113 115 116 114 119 124 121 116 
11 
249
86 A 63 M 162 64 II 114 110 105 110 114 106 110 112 119 109 121 117 120 110 124 113 119 125 119 
12 
255
93 A 58 M 168 63 I 121 110 104 118 120 116 110 116 117 116 110 111 125 114 124 116 125 119 126 
13 
267
36 A 55 M 156 58 I 134 120 122 128 128 123 128 119 118 124 118 111 130 134 126 119 120 114 128 
14 
265
66 A 69 M 149 53 II 112 110 104 96 98 113 109 103 118 120 123 127 120 121 119 126 117 121 124 
15 
304
41 A 61 M 145 55 I 128 120 119 123 119 118 120 119 115 120 110 112 126 134 126 128 118 120 129 
16 
295
10 A 67 M 166 61 I 124 118 114 119 120 116 120 122 126 128 120 121 124 142 100 128 130 128 140 
17 
325
42 A 60 M 150 66 I 127 120 111 122 120 116 128 114 120 118 110 112 135 140 136 122 143 139 144 
18 
338
85 A 65 M 148 63 I 114 110 96 92 98 112 127 113 112 128 112 116 121 129 141 136 124 145 135 
19 
362
26 A 60 M 159 59 I 122 120 116 125 120 120 120 124 116 116 125 111 112 142 139 120 131 140 129 
20 
397
34 A 50 M 149 56 I 125 120 115 112 120 122 128 125 120 125 119 116 118 117 122 119 124 120 127 
21 
154
06 B 66 M 167 64 I 128 124 120 118 120 129 122 126 129 120 117 119 120 121 123 117 114 121 129 
22 
177
73 B 70 M 148 60 II 115 110 96 90 92 95 96 100 118 110 107 118 120 121 119 123 117 122 119 
23 
189
93 B 55 M 156 58 I 127 120 114 100 94 100 110 118 126 114 115 121 122 123 119 122 120 126 129 
24 
198
79 B 61 M 167 57 I 119 110 102 106 112 114 119 120 115 120 110 119 118 125 120 115 119 113 125 
25 
186
59 B 67 M 168 55 II 110 102 96 94 98 110 116 114 112 118 115 117 118 124 117 121 116 112 117 
26 
204
42 B 54 M 166 54 I 124 110 102 100 112 116 115 112 123 110 114 116 125 118 124 116 110 119 126 
27 
212
26 B 63 M 163 57 I 115 110 102 94 100 112 102 110 127 120 115 116 121 118 123 117 113 109 117 
28 
221
50 B 66 M 169 52 I 126 120 110 100 102 108 104 112 118 126 110 119 118 117 120 125 120 115 128 
29 
230
40 B 60 M 158 66 II 129 120 113 112 134 120 118 124 112 124 119 118 120 110 117 121 124 126 130 
30 
262
34 B 55 M 166 57 I 107 100 98 92 94 98 104 109 120 118 114 123 112 114 120 124 119 115 112 
31 
262
02 B 70 M 168 64 I 123 122 120 116 128 114 120 118 110 96 114 118 119 117 114 120 115 117 125 
32 
265
56 B 68 M 146 63 II 108 108 116 112 127 113 112 128 120 114 119 111 114 121 125 120 115 110 119 
33 
281
40 B 54 M 154 55 I 122 125 120 120 120 124 116 116 110 102 121 120 110 119 122 118 114 120 125 
34 
315
04 B 57 M 156 61 I 124 112 120 122 128 125 120 125 118 126 110 119 118 117 113 119 121 124 127 
35 
321
84 B 62 M 152 64 I 126 118 120 129 122 126 129 120 110 115 111 121 118 115 125 127 114 121 125 
36 
335
58 B 65 M 163 59 I 124 124 110 120 108 124 118 110 110 119 120 121 130 119 116 120 115 121 117 
37 
335
53 B 59 M 166 62 I 119 100 110 119 129 124 126 114 120 110 119 124 143 119 122 118 114 110 116 
38 
351
02 B 69 M 163 54 I 110 106 112 114 119 120 115 120 120 113 123 124 124 110 116 120 115 111 116 
39 
352
01 B 60 M 169 59 I 124 116 128 114 120 118 110 114 110 118 125 115 131 113 109 105 110 115 119 
40 
400
19 B 65 M 147 56 I 127 112 127 113 112 128 120 113 119 120 117 109 124 115 110 114 119 123 118 
41 
154
03 C 60 M 142 63 I 130 120 120 124 116 116 110 124 120 118 123 124 114 120 113 109 114 119 123 
42 
175
21 C 61 M 147 60 I 108 122 128 125 120 125 102 125 112 128 109 118 117 110 116 120 114 121 118 
43 
196
43 C 57 M 155 58 I 119 129 122 126 129 120 110 126 116 116 116 114 120 116 120 123 119 115 111 
44 
189
68 C 65 M 166 50 I 124 120 112 100 118 110 110 100 120 125 114 121 119 109 113 118 121 124 120 
45 
201
94 C 65 M 168 55 I 127 100 110 118 126 114 120 118 129 120 121 117 116 112 109 105 110 115 119 
46 
210
44 C 59 M 159 56 I 124 114 119 120 115 120 120 120 118 110 121 124 110 114 122 120 110 116 120 
47 
213
65 C 60 M 148 58 I 125 110 118 126 114 120 112 114 119 110 124 123 113 121 115 119 115 109 113 
48 
221
84 C 58 M 155 52 I 132 119 120 115 120 120 128 114 120 110 112 114 124 115 122 118 114 118 121 
49 
231
72 C 61 M 167 59 I 110 102 98 94 110 110 127 113 112 120 119 117 120 117 111 118 121 124 117 
50 
257
29 C 62 M 163 54 I 118 112 110 96 113 119 120 124 116 120 114 121 120 110 120 125 121 118 124 
51 
267
27 C 58 M 168 60 I 121 116 116 110 124 120 128 125 120 112 110 119 118 120 119 121 124 118 123 
52 
277
90 C 68 M 169 56 I 134 120 125 102 125 112 122 126 129 128 118 117 119 124 123 117 112 109 114 
53 
325
33 C 65 M 168 57 II 112 106 100 94 110 116 120 100 118 127 118 115 127 121 118 123 119 124 117 
54 
346
21 C 63 M 157 53 I 120 118 110 110 100 120 110 118 126 120 130 119 120 121 111 109 114 118 121 
55 
335
52 C 58 M 168 66 I 129 126 114 120 118 129 119 120 115 128 122 119 118 110 120 116 110 114 119 
56 
335
34 C 65 M 164 69 II 119 115 120 120 120 118 118 126 114 122 116 109 119 124 119 114 118 121 117 
57 
350
84 C 59 M 169 62 I 130 125 102 125 118 126 114 120 112 125 121 116 114 115 117 111 118 121 124 
58 
368
49 C 55 M 166 64 II 127 120 110 126 120 115 120 120 128 126 116 110 125 115 110 120 125 121 118 
59 
412
41 C 65 M 156 65 I 120 110 103 96 108 110 114 110 127 100 117 118 122 114 120 119 121 124 118 
60 
396
72 C 64 M 169 55 II 125 114 120 118 128 120 113 119 120 118 120 119 113 121 124 123 117 112 109 
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